Professional Documents
Culture Documents
We are addressing the forecasting of Indian Pharmaceutical Industry through the future
opportunities and the impact of 2010 budget.
In the past few years, the domestic Pharmaceutical industry has witnessed a fast mount in
demand for medicines.
The report discusses about the advent of Indian pharmaceutical industry, the current
scenario, major players in the market, role of pharmaceutical industry in India, recent alliances,
mergers & acquisitions of Indian and foreign companies and finally about CSR activities of the
companies.
We analyzed the future forecast of the industry. Over the next five to ten years, India is
likely to grown-up further as a provider of services across the drug-development spectrum. Thus
Indian pharmaceutical market will undergo a major transformation in the next decade and it will
become one of the top ten markets in the world. There is a need for regulatory reform in India to
encourage leading global players to continue and accelerate the outsourcing of their R&D
activities-beginning with discovery research-to the subcontinent. This is particularly urgent in
the face of the strong competition from China, where the government has been particularly
proactive in encouraging foreign investments in pharmaceuticals and biotechnology.
Global Pharmaceuticals
In late 2003, Britain’s Guardian newspaper commented that, on the face of it, the global
pharmaceutical industry “looks like the epitome of a modern, mature industry that has found a
comfortable way to make profits by the billion: it's global, hi-tech, and has the ultimate
customer, the healthcare budgets of the world's richest countries.”The modern pharmaceutical
industry is a highly competitive non-assembled1 global industry. Its origins can be traced back to
the nascent chemical industry of the late nineteenth century in the Upper Rhine Valley near
Basel, Switzerland when dyestuffs were found to have antiseptic Properties.
Manufacturing industries are important for an economy as they employ a huge share of
the labor force and produce materials required by sectors of strategic importance such as national
infrastructure and defense. Manufacturing industries came into being with the occurrence of
technological and socio-economic transformations in the Western countries in the 18th-19th
century. This was widely known as industrial revolution. Manufacturing industries came into
being with the occurrence of technological and socio-economic transformations in the Western
countries in the 18th-19th century. This was widely known as industrial revolution.
Table 1.1 Top 12 Global pharmaceutical companies (As per 2009 Annual report)
Some facts
• 70% of pharmaceutical drugs are consumed as powders in the form of tablets or capsules.
• Per capita drug expenditure Rs. 220 per annum
Manufacturing industry trends suggest that a tendency for self employment is gradually
catching up in the manufacturing industry scenario. There is a wide disparity between the
ownership rates in the rural areas and the other parts of the country. Records reveal that there
was growth in employment opportunities in the manufacturing industries by 14% between 1994
through 2005. 18% of GDP or gross domestic product in the year 1993 was due to revenues
generated by the manufacturing industry, established according to reports of manufacturing
industry analysis.
• Ethical
• OTC
• Generic and biotech.
Among all the industries, Pharmaceutical Industry is suited best for the Foreign
investors. Foreigners are enctheiraged to participate in the following areas:
Indian Pharmaceutical
Industry
The pharmaceutical industry is one of the fastest growing sectors in India. The market
has maintained a steady growth for the past decade and the production capacity has increased at
the same pace. Import and export trade expected to be active and growing at a double-digit rate.
Foreign investors are flocking into India for a slice of the market. The industry will continue its
growing trend. Like many other sectors in India, the government plays a crucial role. Several
recent changes in policy will reshape the industry and the market. The introduction and success
of penicillin in the early forties and the relative success of other innovative drugs,
institutionalized research and development (R&D) are the successful initiatives of the industry.
The industry witnessed major developments in the seventies with the introduction of
tighter regulatory controls, especially with the introduction of regulations governing the
manufacture of ‘generics’. The industry expanded rapidly in the 1960s, benefiting from
significant new discoveries with permanent patent protection. Regulatory controls on clinical
development and marketing were light and healthcare spending boomed as economies prospered.
There were two important developments in the 1970s. Firstly, the Thalidomide tragedy
(where an antiemetic given for morning sickness caused birth defects) led to much tighter
regulatory controls on clinical trials, greatly increasing development costs. Secondly, enactment
of legislation to set a fixed period on patent protection (typically 20 years from initial filing as a
research discovery) led to the appearance of “generic” medicines. Generics have exactly the
same active ingredients as the original brand, and compete on price.
Global companies prefer and feel that India is the best place for outstheircing. The reasons are:
Competent workforce: India has a pool of personnel with high managerial and technical
competence as also skilled workforce. It has an educated work force and English is commonly
used. Professional services are easily available.
Cost-effective chemical synthesis: Its track record of development, particularly in the area of
improved cost-beneficial chemical synthesis for various drug molecules is excellent. It provides
a wide variety of bulk drugs and exports sophisticated bulk drugs.
Legal & Financial Framework: India has a 53 year old democracy and hence has a solid legal
framework and strong financial markets. There is already an established international industry
and business community.
Information & Technology: It has a good network of world-class educational institutions and
established strengths in Information Technology.
Globalisation: The country is committed to a free market economy and globalization. Above all,
it has a 70 million middle class market, which is continuously growing.
Consolidation: For the first time in many years, the international pharmaceutical industry is
finding great opportunities in India. The process of consolidation, which has become a
generalized phenomenon in the world pharmaceutical industry, has started taking place in India.
Industry Analysis
3.1.1 Strengths
1. Low cost of production.
2. Large pool of installed capacities
3. Efficient technologies for large number of Generics.
4. Large pool of skilled technical manpower.
5. Increasing liberalization of government policies.
6. Massive pharmaceutical market growth potential, highly reliant on modernization and reform.
7. Strong local manufacturing sector with leading domestic players establishing a notable
international presence.
3.1.2 Weakness
1. Fragmentation of installed capacities.
2. Low technology level of Capital Goods of this section.
3. Non-availability of major intermediaries for bulk drugs.
4. Lack of experience to exploit efficiently the new patent regime.
5. Very low investment in R&D.
6. Low share of India in World Pharmaceutical Production (1.2% of world production but having
16.1% of world''s population).
7. Very low level of Biotechnology in India and also for New Drug Discovery Systems.
8. Lack of experience in International Trade.
9. Low level of strategic planning for future and also for technology forecasting.
10.Low expenditure for the health care.
11.Production of duplicate drugs, which is one of the major weakness of the pharma industry.
12.Absence of association between the various pharma institutes and institutions.
3.1.4 Threats
1. Containment of rising health-care cost.
2. High Cost of discovering new products and fewer discoveries.
4. Stricter registration procedures.
5. High entry cost in newer markets.
6. High cost of sales and marketing.
7. Competition, particularly from generic products.
8. Competition from the MNCs
9. More potential new drugs and more efficient therapies.
10. Switching over form process patent to product patent.
11. Small number of discoveries in the products.
12. Outdated method of sales and marketing used in the industry.
13.Non-traiff imposed by developed countries.
1. Today there is political uncertainty in the air. A combination of diverse political thought
have got together to cobble together a rag-tag coalition, that is riddle with ideological
contradictions. Therefore, any consistent political or economic policy cannot be
expected. This muddies the investment field.
2. The Minister in charge of the industry has been threatening to impose even more
stringent Price Control on the industry than before. This is throwing many an investment
plan into the doldrums.
3. DPCO which is the bible for the industry has in effect worked contrary to the stated
objectives. DPCO nullifies the market forces from encouraging competitive pricing of
goods dictated by the market. Now the pricing is determined by the Government based
on the approved costs irrespective of the real costs.
4. Effective January, 2005 the country goes in for the IPR (Intellectual Property Rights)
regime, popularly known as the Patent Act. This Act will impact the Pharmaceutical
Industry the most. Thus far an Indian company could escape paying a patent fee to the
inventor of a drug by manufacturing it using a different chemical route. Indian
companies exploited this law and used the reverse-engineering route to invent a lot of
alternate manufacturing methods. A lot of money was saved this way. This also
encouraged competing company to market their versions of the same drug. That meant
that the impurities and trace elements found in different brands of the same substance
were different both in qualification as well as in quantum.
Product patent regime will eliminate all this. Now, a patented drug would be
manufactured using the same chemical route and would be manufactured by the inventor
or his licentiates using the chemicals with same specifications. Therefore, all the brands
of the same active ingredient would not have any difference in purity and impurities.
The different brands would have to compete on the basis of non input-related innovations
such as packaging, color, flavors, Excipients etc.
This is the biggest change the environment is going to impose on the industry. The
marketing effort would be now focused on logistics, communications, economy of
operation, extra-ingredient innovations and of course pricing.
5. In Pharma industry there is a huge PSU segment which is chronically sick and highly
inefficient. The Government puts the surpluses generated by efficient units into the price
equalization account of inefficient units thereby unduly subsidizing them. On a long
term basis this has made practically everybody inefficient.
6. Effective the January, 2005 the Government has shifted from charging the Excise Duty
on the cost of manufacturing to the MRP thereby making the finished products more
costly. Just for a few extra bucks the current government has made many a life saving
drugs unaffordable to the poor.
7. The Government provides extra drawbacks to some units located in specified area,
providing them with subsidies that are unfair to the rest of the industry, bringing in a
skewed development of the industry. As a results Pharma units have come up at place
unsuitable for a best cost manufacturing activity.
1. India spends a very small proportion of its GDP on healthcare ( A mere 1% ). This has
stunted the demand and therefore the growth of the industry.
2. Per capita income of an average Indian is low ( Rs. 12,890 ), therefore, spending on the
healthcare takes a low priority. An Indian would visit a doctor only when there is an
emergency. This has led to a mushrooming of unqualified doctors and spread of non-
standardized medication.
3. The incidence of Taxes are very high. There is Excise Duty ( State & Central), Custom
Duty, Service Tax, Profession Tax, License Fees, Royalty, Pollution Clearance Tax,
Hazardous substance (Storage & Handling) license, income tax, Stamp Duty and a host
of other levies and charges to be paid. On an average it amounts to no less than 40-45%
of the costs.
5. There are only 50,00,000 Medical shops. Again this affects adversely the distribution of
medicines and also adds to the distribution costs.
6. India is a high interest rate regime. Therefore the cost of funds is double that in America.
This adds to the cost of goods.
7. Adequate storage and transportation facilities for special drugs is lacking. A study had
indicated that nearly 60% of the Retail Chemists do not have adequate refrigeration
facilities and store drugs under sub-optimal conditions. This affects the quality of the
drugs administered and of course adds to the costs.
8. India has poor roads and rail network. Therefore, the transportation time is higher. This
calls for higher inventory carrying costs and longer delivery time. All this adds to the
invisible costs. Its only during the last couple of years that good quality highways have
been constructed.
1. Poverty and associated malnutrition dramatically exacerbate the incidence of Malaria and
TB, preventable diseases that continue to play havoc in India decades after they were
eradicated in other countries.
2. Poor Sanitation and polluted water sources prematurely end the life of about 1 million
children under the age of five every year.
3. In India people prefer using household treatments handed down for generations for
common ailments.
6. Smoking, gutka, drinking and poor oral hygiene is adding to the healthcare problem.
9. Early child bearing affects the health standards of women and children.
10. Ignorance of inoculation and vaccination has prevented the eradication of diseases like
polio, chicken-pox, small-pox, mumps and measles.
11. People don’t go in for vaccination due superstitious beliefs and any sort of ailment is
considered as a curse from God for sins committed.
1. Advanced automated machines have increased the output and reduced the cost.
3. Newer medication, molecules and active ingredients are being discovered. As of January
2005, the Government of India has more than 10,000 substances for patenting.
4. Ayurveda is a well recognized science and it is providing the industry with a cutting
edge.
6. Humano-Insulin, Hepatitis B vaccines, AIDS drugs and many such molecules have given
the industry a pioneering status.
8. The huge unemployment in India prevents industries from going fully automatic as the
Government as well as the Labor Unions voice complains against such establishments.
In today’s competitive world, where a perfect competition is going on in the business, the
profit of the company operate in that particular industry may go zero. But it is not possible;
because no company will be a price taker. Secondly, they strive to create a competitive
advantage to thrive in the competitive scenario. Michael Porter, considered to be one of the
foremost gurus' of management, developed the famous five-force model, which influences an
industry.
In Short;
Pharma industry is one of the most competitive industries in the country with as many as
10,000 different players fighting for the same pie. The rivalry in the industry can be gauged from
the fact that the top player in the country has only 6% market share, and the top five players
together have about 18% market share. Thus, the concentration ratio for this industry is very
low. High growth prospects make it attractive for new players to enter in the industry.
Another important factor for the industry rivalry is the fact that the entry barriers to
pharma industry are very low. The fixed cost requirement is low but the need for working capital
is high. The fixed asset turnover, which is one of the gauges of fixed cost requirements, tells us
that in bigger companies this ratio is in the range of 3.5 to 4 times. For smaller companies, it
would be even higher.
Many smaller players that are focused on a particular region, have a better hang of the
distribution channel, making it easier to succeed, albeit in a limited way.
An important fact is that pharma is a stable market and its growth rate generally tracks
the economic growth of the country with some multiple (1.2 times average in India). Though
volume growth has been consistent over a period of time, value growth has not followed in
tandem.
The product differentiation is one key factor, which gives competitive advantage to the
firms in any industry. However, in pharma industry product differentiation is not possible since
India has followed process patents till date, with laws favoring imitators. Consequently, product
differentiation is not the driver, cost competitiveness is.
Going forward, we foresee increasing competition in the industry but the form of
competition will be different. It will be between large players (with economies of scale) and it
may be possible that some kind of oligopoly or cartels come into play. This is owing to the fact
that the industry will move towards consolidation. The larger players in the industry will survive
with their proprietary products and strong franchisee.
The unique feature of pharma industry is that the end user of the product is different from
the influencer (read doctor). The consumer has no choice but to buy what doctor says. However,
when we look at the buyer's power, we look at the influence they have on the prices of the
product.
In pharma industry, the buyers are scattered and they as such does not wield much power
in the pricing of the products. However, government with its policies plays an important role in
regulating pricing through the NPPA (National Pharmaceutical Pricing Authority).
The pharma industry depends upon several organic chemicals. Like the Pharma industry
the chemical industry is also very competitive and fragmented. The chemicals used in the
pharma industry are largely a commodity.
So the suppliers have very low bargaining power and the companies in the pharma
industry can switch from their suppliers without incurring a very high cost.
However, what can happen is that the supplier can go for forward integration to become a
pharma company. Companies like Orchid Chemicals and Sashun Chemicals were basically
chemical companies, who turned themselves into pharmaceutical companies.
However, creating brand awareness and franchisee amongst doctors is the key for long-
term survival. Also, quality regulations by the government may put some hindrance for
establishing new manufacturing operations.
The barriers to entry will increase in the future. The change in the patent regime, will see
new proprietary products coming up, making imitation difficult. The players with huge capacity
will be able to influence substantial power on the fringe players by their aggressive pricing
which will create hindrance for the smaller players.
However, in recent times, the advances made in the field of biotechnology, can prove to
be a threat to the synthetic pharma industry.
Industry Trends
The largest acquisitions in the industry during last years were the acquisition of
Pharmacia by Pfizer (purchase price $58 billion), and acquisition of Guidant by Johnson &
Johnson (purchase price $25 billion). Both acquisitions allowed these two U.S.-based companies
to solidify their places among the elite of the pharmaceutical industry. European companies were
even more aggressive in M&A activity than their American competitors – 3 out of 6 major
European companies underwent mergers during the last several years: GlaxoSmithKline (merger
of Glaxo Wellcome and SmithKline Beecham), AstraZeneca (merger of Astra and Zeneca) and
Sanofi-Aventis (merger of Sanofi-Synthelabo and Aventis).
Another form of structural change in the industry was establishing of new strategic
alliances and joint ventures. So far as the research and development process for each drug take
many years and requires significant investments, and the outcome of these investments of time
and financial resources remains unclear until the final approval of the drug, “Big Pharma”
companies are constantly looking for synergies that they can get from cooperation with their
competitors. Last years gave multiple examples of such initiatives. For example, cooperation of
Sanofi-Aventis and Bristol-Myers Squibb resulted in production of Plavix, which is currently
one of the top-selling products for each of these companies.
Finally, “Big Pharma” companies in order to maintain strong sales growth and meet
profitability expectations of their shareholders were actively selling low-profitability or non-core
businesses. For example, in 2003 Merck sold its low-profitability Medco Health Solutions that
helped to increase its profitability margin. Massive sales of non-pharmaceutical businesses by
Takeda also were compatible with its strategy to concentrate its financial resources on its core
pharmaceutical business.
The pharmaceutical industry showed high sales growth rates in the recent past, and a
number of factors suggest that this trend will continue in the future.
First, due to numerous advancements in science and technology, including those in the
health care industry, life expectancy in the developed countries has been steadily growing. As
the result, growing proportion of elderly people promises further growth of demand for
healthcare products. Also, according to various studies, a significant portion of elderly
population in the United States and other countries does not receive proper treatment. For
example, only about one third of the U.S. population who requires medical therapy for high
cholesterol is actually receiving adequate treatment. As it is expected, the Medicare Prescription
Drug Improvement and Modernization Act starting from the beginning of 2006 will increase
access of senior citizens to the prescription drug coverage, thus increasing pharmaceutical sales.
One of the distinctive characteristics of the “Big Pharma” companies is a very high level of
investments in research and development. On average, it takes about 10-15 years, and millions of
dollars to develop a new medicine. According to industry statistics, only about one in ten
thousand chemical compounds discovered by pharmaceutical industry researchers proves to be
both medically effective and safe enough to become an approved medicine, and about half of all
new medicines fail in the late stages of clinical trials. Not surprisingly, according to “Research
and Development in Industry: 2001” report of the National Science Foundation, in 2001 the
pharmaceutical industry had one of the highest R&D expenditures as percentage of net sales.
To determine the opportunities and threats those exist for firms within a competitive
environment.
To analyze both the quantitative and qualitative aspects of the top performing companies
in India.
The companies are selected it’s based on the Turnover. The Top 5 players based on the 2008
Turnover are selected and listed here:
Company Profile
5.1 RANBAXY
Mission
Vision
Achieve Significant Business in proprietary prescription products by2012 with a strong presence
in developed markets.
Overview
Ranbaxy was incorporated in 1961 and went public in 1973. Ranbaxy Laboratories
Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated, research based,
international pharmaceutical company, producing a wide range of quality, affordable generic
medicines, trusted by healthcare professionals and patients across geographies.
In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator
companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical
powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies,
globally. The Company’s business philosophy based on delivering value to its stakeholders
constantly inspires its people to innovate, achieve excellence and set new global benchmarks.
Driven by the passion of its over 12,000 strong multicultural workforce comprising 50
nationalities, Ranbaxy continues to aggressively pursue its mission to become a Research-based
International Pharmaceutical Company.
Business Performance
Amidst a challenging business environment, Ranbaxy has achieved a growth of 4% on its
top line. This was supported by the Company's focus on emerging markets, that contributed 54%
to the business; consolidation in the business in developed markets and continued investment in
building a high-value new product pipeline. Russia, Ukraine, Brazil and India led the growth in
the emerging markets. The Company recorded a strong performance in these markets that was
higher than the industry averages. Amongst the developed markets, Canada and Japan
outperformed while Germany and France delivered good results. For the first time, Ranbaxy
launched Authorised Generics, Omeprazole and Felodipine, in USA. On both these products, the
company performed well and garnered good market positions.
The business in both emerging and developed markets was supported by increased
number of new product launches and continuous focus on key emerging therapies. On the
innovation front, R&D saw a series of positive developments during the year. The company
expanded their Drug Discovery & Development collaboration model by successfully entering
into a new collaboration with Merck in the field of anti-infectives. In their GSK alliance, the
company maintained steady progress during the year, filing an IND (Investigational New Drug)
application in India for Phase I trials on the Respiratory molecule. Their Anti-Malaria
combination molecule, Arterolane, progressed well, having successfully completed Phase II
studies and obtained approval for Phase III studies in India. On the generics side, the company
continue to drive a high value pipeline of differentiated and niche products to achieve greater
productivity at the business end.
The year 2008 witnessed an unprecedented economic downturn across all markets
globally. The volatility and uncertainty in the financial environment was exceptionally high and
led to sharp fluctuation in foreign currency rates. Since their business is spread widely across
multiple geographies and foreign currencies, the weakened and fluctuating financial and Forex
environment created a substantial negative impact on their profitability for the year inspite of
sustained performance, at an operating level.
Ranbaxy, in 2008, proactively adopted the latest financial guidelines (AS-30) related
with foreign currency instruments and harmonised its financial reporting accordingly. The
company were amongst the earliest companies in India to adopt these guidelines, ahead of time,
thus aligning their Company with the global reporting norms while maintaining high standards
of disclosure and complete transparency. For the year 2009, Ranbaxy has a clear strategy to
harness its growth potential in emerging markets, rebuild the US business through a series of
actions on products and facilities; actualise significant revenue upsides through First-to-File and
Day-1 launches; strengthen the product / therapeutic pipeline and look for M&A opportunities,
complementing their geographic and therapeutic basket. Their focus will be to resolve regulatory
compliance issues and continue to strengthen GMP across all locations. Besides this, Ranbaxy
and Daiichi Sankyo will identify key projects to realise synergies at both the front and back ends
of the business, although, there will be much to contend with, considering that the industry is
projected to grow at around 5% in 2009.
Ranbaxy Global Consumer Healthcare (RGCH) has achieved a distinction for its
Revital brand being in the top 15 pharmaceutical brands in India. This is now a US $ 44 Mn
business, growing well consistently. During 2008, RGCH also launched Volini SR 100 in the
Analgesics category and Chyawan Active, a sugar free Chyawanprash. Finally, the API
Business is a global US $ 120 Mn business, with good support from Ranbaxy Chemical
Research. The Company's Global ARV business continues to perform well, with sales of US
$53 Mn during the year. In this period ARVs were supplied for treatment programs in various
countries across the developing world. Further, the World Health Organization (WHO), Geneva,
included three additional ARV products of the company in its pre-qualification list - Abacavir
tablets, Fixed Dose Combination (FDC) tablets of Abacavir, Lamivudine and Zidovudine and
FDC tablets of Lamivudine, Zidovudine and Nevirapine. This has taken the total number of
It is their constant endeavtheir to scale up and better their Occupational Health and Safety
practices. A number of initiatives were undertaken during the year to enhance workplace safety.
The emergency preparedness was ensured through regular tabletop exercises and mock drills at
all thier manufacturing facilities and R&D centre’s. At their Toansa manufacturing facility, the
'Fire and Safety Risk Assessment' and the 'Hazardous Area Classification' was reviewed by third
party specialists. The National Safety Council also conducted external safety audits at Toansa
and Mohali. A cross functional team of Corporate EHS, Engineering and Facility professionals
along with an external specialist further undertook external safety audits at the Corporate Office.
Extensive safety training programs were also conducted by internal and external specialists at all
their manufacturing facilities, including those managed by their contract manufacturing business
partners. These diligent steps have led to the development of an extremely positive atmosphere
at all their locations with Environment, Health and Safety being given due importance. These
best practices are now a part of the system and are deeply ingrained into the very fabric of their
operations.
The Company received two warning letters from the United States Food & Drug
Administration (US FDA) on September 16, 2008 for two of its manufacturing sites located at
Paonta Sahib and Dewas in India. Simultaneously US FDA also issued an import alert for
products manufactured at these two plants. Further, on February 25, 2009, the Company received
a letter from the US FDA indicating that the Agency has invoked its Application Integrity Policy
(“AIP”) against Paonta Sahib facility (the “facility”). The US FDA has tested and analysed many
products of the Company and has found them meeting applicable specification. US FDA has
consistently maintained after above letters that the Company’s products meet their quality
specifications, and there are no health risks associated with the Company’s products.
Importantly, no other Ranbaxy plants, in India, or anywhere globally, are covered by this latest
action. The Company continues to fully co-operate with the concerned authorities for their final
clearance, pending which the company could continue to face delays for new product approvals
and sales of existing products to the US.
5.2 CIPLA
Mission
• To contribute to continued medical education and research into new drug delivery
systems in the belief that this contribution will improve technical know-how and
ultimately benefits all patients in South Africa.
• To be the employer of choice in the pharmaceutical sector developing our most valuable
asset, human capital, irrespective of race, colour or creed so that they may realise their
full potential and ambitions. We pledge personal respect, fair compensation and a clean
and safe working environment.
Vision
To heal South Africa and to become the biggest and the most admired
pharmaceutical company in South Africa.
Overview
Cipla was established in 1935. Cipla exports raw material, intermediates, prescription
drugs, OTC products and veterinary products. Cipla products are bought by over 180 countries
in the world. The range of services include consulting, project appraisal, engineering, plant
supply, commissioning, training, operation management support, and quality control.
Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, the companyight control,
depression and many other health conditions, and its products are distributed in more than 180
countries worldwide. Cipla has recently launched i-Pill which is a single dose emergency
contraceptive and has acquired a great deal of popularity in a short span of time. Other latest
launches of Cipla include products such as Nova, Moxicip, Flomex, Fullform, Montair LC, and
Imicrit.
Business Performance
The Company’s turnover recorded a 22 per cent growth and crossed the Rs.5000 crore
milestone. While exports grew by 30 per cent, the domestic sales grew by 15 per cent. Notably,
technical fees fetched Rs.218 crore, marking a significant 42 per cent growth over the previous
year. However, forward contracts entered into to hedge the Company’s foreign exchange
business had an impact on net profit growth. According to ORG-IMS, Cipla remained the leader
in the domestic market, as on 31st March 2009.
Manufacturing Facilities
Over the last three years, the Company has invested about Rs.1900 crore in fixed assets.
This major expansion programme will help meet the increasing demands of domestic and
international business and to sustain growth. It will also help take advantage of taxation and
other fiscal benefits. The construction work at the Company’s Rs.750 crore Special Economic
Zone (SEZ) project for pharmaceutical formulations, at Indore, Madhya Pradesh, is in full swing.
Alliance Business School Page 41
This project includes facilities for the manufacture of aerosols, respules, liquid orals, pre-filled
syringes (PFS), nasal sprays, large volume parenterals (LVP), eye drops, tablets and capsules.
During the current year, the Company proposes to take validation batches for these dosage forms
and commercial production is expected to commence in the subsequent year. Cipla’s Rs.310
crore project in Sikkim for the manufacture of formulations including capsules, tablets, nasal
sprays, inhalers, eyedrops and respules commenced commercial production during the year.
Work at the Company’s SEZ project at Kerim, Goa remained suspended due to the stop-work
order issued by the State Government. The Company has received a communication dated 11th
July 2008 from the government revoking the stop-work order, consequent to the filing of a
petition by the developer of the SEZ against the order. The petition is currently pending before
the Goa bench of Bombay High Ctheirt.
Drug Pricing
The drug pricing policy has not been announced for more than five years. It is hoped the present
government will address this issue with some sense of urgency. The government must take the
lead and announce a policy which is fair, transparent and against monopoly. The company have
always maintained that free and open competition is the best way to control drug prices. As
stated earlier, Cipla is willing to share its pharmaceutical technology with the government of
India, free of charge, so that the public sector pharmaceutical undertakings can also manufacture
and market all vital and life-saving drugs at economical prices.
Vision
Overview
Sun Pharma came into existence as a start-up in 1983. They make speciality
pharmaceuticals and active pharmaceutical ingredients. With world-class technology and a team
of strong professionals, the company have built sites and systems that meet the most stringent
international manufacturing standards. Expert quality teams ensure that systems and processes
remain in compliance with the latest standards. In 1996, a mixture of acquisitions like Chattem
limited, Taro pharma, Able labs etc.
The company tries to work by these principles in all its interactions with stakeholders,
including shareholders, employees, customers, suppliers and statutory authorities.
Important mergers were those of the US, Detroit based Caraco Pharm Labs.
The company recorded sales of Rs. 42,723 million, a growth of 27% over the previous
year Between Sun Pharma and Caraco, 38 ANDAs were filed covering 37 products 42 products
were launched in India and ANDAs for 18 products were approved for the US The company
received the first approval for a controlled substance ANDA from their Cranbury, New Jersey
facility Their expansion plans at Dadra, Halol and Detroit are being completed as per Schedule
Sun Pharma's annual sales for 2008-09 was Rs. 42,723 million, a growth of 27% over the
previous year. The cumulative spend onR&Dover the years now amounts to Rs. 15 billion. In
line with their intent of becoming an international generic pharma company, sales from
international markets grew to 53% of their total turnover. Sales at Caraco were
down4%toUSD337 million.
Products
Sun Pharma's product portfolio consists of 4 main categories of products:
1. India Branded Generics
2. US Generics
3. International Branded Generics
4. Active Pharmaceutical Ingredients (API)
Business Performance
Sales of branded prescription formulations in India were at Rs. 4,473 million for the
second quarter, a growth of 20% over the same quarter last year, contributing 37% of total sales.
For the first half, domestic formulation sales were at Rs. 8,769 million, an increase of 19% over
first half last year. Sun Pharma holds 3.4% market share in the highly competitive pharma
market, as per latest IMS ORG report. 9 key products were launched during the quarter, taking
the total for H1 to 16. Sun Pharma continues to sell generic Protonix and Ethyol, products that
were Company’s “at-risk” launches. This quarter and half year too, these launches had a one-off
effect on the US generic sales and profits. Sun Pharma subsidiary, Caraco Pharmaceutical
Market scenario
The generics market remains a major growth area in the global healthcare arena. It
continues to grow at a faster pace than the global pharma market, largely due to regular patent
expirations of blockbuster drugs. Rising healthcare expenditure also contributes to industry
Europe is a region where the company intend to increase their generic focus in the years
to come. According to European Generic medicines Association's (EGA) Market Review 2007,
the EU generic medicines market was aboutUSD31 billion.The company continue with their
efforts to enter key markets with a limited number of complex generic products viz. injectables
initially. The company will then offer more products and selectively build up a portfolio in this
market.
India is on its way to become a global leader in API production The Indian API manufacturing
industry is projected to make sales of USD 4.8 billion by 2010, exhibiting an average yearly
growth rate of over 19%. Though, there was a global slowdown in the API market in 2008 due to
the recession, long term prospects continue to be promising. With their rational costs, rapid
speed to market and strong regulatory capability (133 DMF/CEP have been approved or are
awaiting approval), Sun Pharma is well placed to capitalize on this opportunity.
Around 160 specialty APIs are produced across 8 world-class locations, all of which are
ISO 14001 and ISO 9002 approved, besides being approved by the respective foreign regulatory
authorities. 6 of these are in India while the company have one plant each in Hungary and USA
for the manufacture of APIs for controlled substances.The company also have standalone units
in their plants in India for the manufacture of peptides, anticancers, steroids and sex hormones.
A large part of their API capacity is used for in-house consumption. During 2008-09,
their API sales grew to Rs. 4,846 million, contributing 11% to their total turnover. This segment
has been growing at a 3 yearCAGRof 21%. 78% of API sales come from international markets.
The European market has performed well for us this year with older products like 5ASA,
Pentoxifylline and Clomipramine in which the company have good market shares. Their
integration into API manufacturing is an important part of their business. It strengthens their
Indian and developing markets business, and their ability to take on challenges in the US generic
market. This year, the company scaled up 30APIs. This brings their total regulated market
approvedAPI to 81 of 133 filings made forDMFandCEP.
Vision
To bring innovative products for the healthcare professional to improve the health and
well being of individuals.
Lupin Pharmaceuticals, Inc. is well positioned for growth in the US market. We can capitalize
on the strengths of our parent company, Lupin Limited:
• Scientific expertise to develop new and improved products and product line extensions;
• Manufacturing technology, expertise and infrastructure;
• Financial resources.
Overview
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited,
For the financial year ended March 2008, Lupin Limited's Revenues and Profit after
Tax were Rs.27, 730 million (US$ 694 million) and Rs.4, 083 million (US$ 102 million)
respectively.
Lupin Research Park (LRP) at Pune, spread across 19 acres is the hub of the Company’s
global research activity. The Centre harbours a culture that fosters innovation and helps shape
inventions into innovative commercial products. The Company also has an advanced Research
& Development facility - Kyowa Pharmaceutical Industry Co. Ltd, located at Osaka, Japan.
• Generics Research
o Formulations Research
o Process Research
• Advanced Drug Delivery Systems (ADDS)
• Lupin BioResearch Centre
• Intellectual Property Management
• Novel Drug Discovery & Development
• Biotechnology Research
Products
a) Generics
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003
with the ANDA approval for cefuroxime axetil. Since then we have received more than a
dozen FDA approvals. Six of Lupin's 14 ANDA approvals were the first granted by the US
FDA, reinforcing our ability to submit high quality dossiers and gain on time approvals. They
vertically integrated, from process development of the API to the submission of dossiers for
finished dosages.
Expanding the product portfolio, Lupin Pharmaceuticals, Inc. is geared to file 15 or more
ANDA’s per year in some of the following areas:
b) Specialty
c)API
Lupin is recognized as a leading manufacturer of cephalosporin API’s, with FDA
approval to manufacture complex oral and injectable cephalosporins.
Lupin is fast gaining share in the cardiovascular segment manufacturing a wide range of
ACE-inhibitors and cholesterol reducing agents.
Lupin’s capabilities in sterile processing, synthetic process development and
fermentation skills coupled with its intellectual property strengths, puts the company in a
very strong position to offer a diverse portfolio of niche API’s to its customers.
Business Performance
CSR activities:
• .Lupin Human Welfare & Research Foundation was set up on October 2, 1998
with the objective of providing an alternative model of rural development in the
country, which is sustainable, replicable and ever evolving.
• LHWRF Foundation has been successful in making a big difference in the
development of poverty-ridden villages, and especially in the life of the poorest of
the poor and empowerment of large number of women in these areas. Today
LHWRF on its part is a catalyst, and an observer of a self-evolving, self-
sustaining spectacular transformation.
• Lupin HWRF has taken following innovative and new initiatives under its CSR
activities:
Dr. Reddy's Laboratories was founded in 1984 by Dr Anji Reddy. In 1986, Dr. Reddy's went
public and entered international markets with exports of Methyldopa. In 1987, Dr. Reddy's
obtained its first USFDA approval for Ibuprofen API and started its formulations operations. In
1988, Dr. Reddy's acquired Benzex Laboratories Pvt. Limited to expand its Bulk Actives
business. In 1990, Dr. Reddy's, entered a new territory when it, for the first time in India,
exported Norfloxacin and Ciprofloxacin to Europe and Far East. In 1993, Dr. Reddy's Research
Foundation was established and the company started its drug discovery programme. In 1994, Dr.
Reddy launched a GDR issue of US$ 48 million. In 1995, the company set up a joint venture in
Russia. In 1997, Dr. Reddy's became the first Indian pharmaceutical company to out-license an
original molecule when it licensed anti-diabetic molecule, DRF 2593 (Balaglitazone), to Novo
Nordisk. In 1998, Dr. Reddy's licensed anti-diabetic molecule, DRF 2725 (Ragaglitazar), to
Novo Nordisk. In 1999, the company acquired American Remedies Limited, a pharmaceutical
company based in India. In the year 2000, became the first Asia Pacific pharmaceutical
company, outside Japan, to be listed on the New York Stock Exchange. In 2001, Dr. Reddy's
Custom Pharmaceutical Services: Dr. Reddy's executes cost-effective and time-bound projects
for its customers, and provides them cGMP-compliant products manufactured in FDA-inspected,
ISO-certified facilities.
Generic Dosages: Dr. Reddy's Lab is a leading generic drugs manufacturer. It is the fourth
largest player in Germany after the acquisition of betapharm. The company has expertise in
customer-specific packaging, compliance packaging, anti-counterfeit packaging, and has won
several awards globally for its packaging efforts, including the Asia Star, AmeriStar and
WorldStar awards.
Branded Dosages: Dr. Reddy's brands such as Omez (Omeprazole), Nise (Nimesulide), Stamlo
(Amlodipine), Ciprolet (Ciprofloxacin), Enam (Enalapril) and Ketorol (Ketorolac) are leaders in
their category in several countries.
Biopharmaceuticals: Grafeel (Filgrastim) was the first biologics product by Dr. Reddy's to
enter the market. The company's second product Reditux (Rituximab) is the first biosimilar
monoclonal antibody to be developed and launched anywhere in the world.
• Dr. Reddy's is the 1st Asia Pacific pharmaceutical company, outside Japan to be listed on
the New York Stock Exchange.
• Dr. Reddy's biologics product Reditux (Rituximab) is the first biosimilar monoclonal
antibody to be developed and launched anywhere in the world.
CSR activities:
They focus on the Foundation of Education & Livelihood creation through its various
Livelihood Advancement Business Schools (LABS) and through its many innovative initiatives
in the School Education space.
• Michael & Susan Dell Foundation In partnership with this Foundation, DRF has
undertaken to provide sustainable livelihood training to 6000 youth from slum
pockets.
• Under the ‘Aarogya’ program, over 75 mobile food vendors in Karimnagar (AP)
have been assisted in developing their businesses.
• Under the ‘Sayodya’ program, 25 partially disabled youth in RR District (AP)
have been assisted in earning their livelihoods through corn vending in specially
designed kiosks.
Comparative Analysis
Interpretation
Interpretation
Cipla has maintained very high inventory levels which is the reason for their appreciable
difference between their current ratio and quick ratio and thus they must take steps to bring
down their inventory level to improve their cash position.Sun pharma has maintained a very
high quick ratio which is very high as compared to industry averages and it also had very high
inventory levels which was taken care during the period 2007-08 and 2008-09.Although their
inventory levels didn’t change much but there was an increase in the amount of sundry
debtors which helped them to perform in sync with industry averages. For Ranbaxy the quick
ratio is very low owing to the number of acquisitions taken up by the company which
deteriorated their cash position. Increasing inventory levels are also a cause of concern for Dr.
Reddys but they have been most effective among all the companies to maintain their quick ratio
close to industry averages.
Cipla has a very high value of the ratio as compared to industry average shows that the
company takes a lot of time to convert its credit sales to cash. Sun pharma has a very low value
of the ratio which is not a desirable situation as it shows that the company gives a very low credit
period which discourages its clients. Ranbaxy is the most efficient company ion this respect as it
has its value closest to industry average. Lupin and Dr. Reddy have been able to keep their
ratios close to industry average throughout the considered period.
Interpretation
Sun pharma has been able to increase its interest coverage ratio to inflationary levels as
it has reduced its debt to nil by the year 2009 which has resulted in no interest obligations thus
no part of their profit is required to cover the interest on the debt. Ranbaxy has performed
abysmally poor as it has invested its funds for acquisition which means that it has been unable
to cover its debts. In 2008 the ratio went negative which is an alarming situation and was
followed by acquisition of the company by Daiichi Sankyo. Lupin is also not performing well
and must bring down its debts because the margin of interest covered by net profits is very poor.
Cipla again has emerged as the best performer as it has performed as per the industry averages.
Cipla which has been the market leader and an efficient performer has low values of EPS
owing to plans of its expansion in centers like Goa, Sikkim and Indore which is funded by a
mix of debt and equity and thus it is an attractive bet for long term investors. Ranbaxy has
showen a remarkable dip in EPS values which became zero in 2008 as it was not able to pay any
dividends as its profits went negative. All the other players have been efficient in maintaining a
high value of EPS.
AVERAGE
3.867488 3.628873 3.792765 2.991357
Interpretation
Cipla has a low ratio compared to industry as although there was an increase in its net
sales but at the same time its fixed assets have also grown in value and the proportional change
in the value of the assets is more than the change in the sales volume. The high value for Sun
pharma over the considered period is because the sales showed a tremendous growth and the
change in the value of net stock was not appreciable. Dr. Reddy has a very impressive value of
the ratios because of a significant increase in its net sales and thus has been successful in
converting its fixed assets to sales.
Interpretation
Alliance Business School Page 72
This ratio tells us that how quickly a company completes its working capital cycle to
convert its working capital back to cash at just enough inventory levels. Cipla has been very
effective in keeping its ratio way below the industry average while Sun pharma and Dr. Reddy
have never been able to achieve a performance at par with the industry because of their
increasing inventory. Lupin is a significant improver in this contrast as it has managed to bring
down its ratios for thye year 2008 and 2009. Ranbaxy on the other hand was doing well till the
year 2007.
Interpretation
Ranbaxy has shown a very poor performance as in other ratios because of their falling
profits which turned negative in the year 2008. All the other companies have been effective in
converting their fixed assets to profits. Dr. Reddy has a low value in the year 2006 because of
low profits that year.
Interpretation
Ranbaxy has consistently shown a decline over the years in its return to the shareholders
as its profits have been low owing to the number of acquisitions taken up by the company. Dr.
Reddy has also a sharp decline from the year 2007 to 2008 as the profits have shown a 60%
decline in this period. All the other companies have been effective in giving the shareholders a
consistent return on their investments.
Interpretation
The ratios for Ranbaxy for the year 2009 were not available as it has not yet disclosed its annual
report for the year. Thus Ranbaxy has not been considered while interpreting the performance of
the companies in the year 2009.
Growth Drivers
For the next 15 years we expect average annual growth in India of 6-7%.2 Strong income
growths will broaden the middle class, an important group for foreign drugs manufacturers, as it
has considerably higher incomes at its disposal than average Indians. Already today, nearly 60
millions people in India’s middle class, with disposable incomes of Rs.2, 18,807.23 to Rs.1,
062,777.96 p.a., can afford western- produced medicines. Until 2025 their number looks set to
rise to approx. 580 millions (+12% p.a.).
Source: www.ibef.org
The fact that despite the low level of unit labour costs India boasts a highly skilled workforce has
enabled the country's pharmaceutical industry at a relatively early stage to offer quality products
at competitive prices. Each year, roughly 115,000 chemists graduate from Indian universities
with a master’s degree and roughly 12,000 with a PhD. The corresponding figures for Germany
– just under 3,000 and 1,500, respectively – are considerably lower. After many chemists from
India migrated to foreign countries over the last few years, they now consider their chances of
employment in India to have improved. As a result, a smaller number is expected to go abroad in
the coming years; some may even return.
Failure of the new patent system: Prerequisites associated with Sec 3(d) of the Patent
(Amendment) Act 2005 restrict the copyright of an existing drug. Moreover, mandatory
licensing permits Indian companies to keep producing generics of copyright products for
overseas selling to underdeveloped nations.
Lack of proper infrastructure: Issues associated with regular power cuts and lack of
suitable transport infrastructure will decelerate the expansion of the sector.
Inadequate funds: Restricted funding from FIs, venture capitalists and the government
may decelerate the expansion of biotechnology sector in India.
Future Prospects
The dream of Indian pharmaceutical companies for marking their presence globally and
competing with the pharmaceutical companies from the developed countries like Europe, Japan,
and United States is now coming true.
The new patent regime has led many multinational pharmaceutical companies to look at
India as an attractive destination not only for R&D but also for contract manufacturing,
conduct of clinical trials and generic drug research. With market value of about US$ 45
billion in 2005, the generic sector is expected to grow to US$ 100billion in the next few years.
The Indian companies are using the revenue generated from generic drug sales to
promote drug discovery projects and new delivery technologies. Contract research in India is
also growing at the rate of 20-25% per year and was valued at US$ 10-120million in 2005. India
is holding a major share in world's contract research business activity and it continues to expand
its presence.
Clinical Research Outsourcing (CRO), a budding industry valued over US$ 118 million
per year in India, is estimated to grow to US$ 380 million by 2010, as MNCs are entering the
market with ambitious plans.
By revising its R&D policies the government is trying to boost R&D in domestic pharma
industry. It is giving tax exemption for a period of ten years and relieving customs and excise
duties of all the drugs and material imported or exported for clinical trials to promote innovative
R&D.
The government has taken various policy initiatives for the pharmaceutical sector:
The government has offered tax breaks to the pharmaceutical sector. Units are eligible
for weighted tax deduction at 150 per cent for the research and development (R&D)
expenditure incurred.
Steps have been taken to streamline procedures covering development of new drug
molecules and clinical research.
The government has launched two new schemes—New Millennium Indian Technology
Leadership Initiative and the Drugs and Pharmaceuticals Research Programme—
especially targeted at drugs and pharmaceutical research.
Investment
The drugs and pharmaceuticals sector has attracted foreign direct investment (FDI) worth
US$ 1.43 billion between April 2000 and December 2008.
Budget measures:
Budget 2009–2010 reduced the customs duty from 10 per cent to 5 per cent on imports of
select life saving drugs and their bulk drugs for treating ailments such as breast cancer,
hepatitis, rheumatic arthritis, etc.
Customs duty has been reduced from 7.5 per cent to 5 per cent on two specified life
saving devices used in the treatment of heart conditions. These devices are now fully
exempt from excise duty and countervailing duty (CVD) also.
Policy changes:
The government has approved the Drugs and Cosmetic (Amendment) Bill, 2008, which
inter alia enhances the term for imprisonment from five years to at least 10 years, which
may extend to lifetime, and raises the fine from Rs.10, 000 to Rs. 10, 00,000 or three
times the value of the drug confiscated, for manufacturers of spurious and adulterated
drugs.
The DCGI has directed state drug regulators not to allow companies to sell drugs that
have undergone a composition change under their old brand names. Such drugs will be
treated as new drugs and the companies would have to go through scrutiny before getting
fresh approvals.
The DCGI has withdrawn the powers given to state-level regulators to issue Certificate of
Pharmaceutical Product (CoPP).
The DCGI has discontinued issuance of the WHO-GMP certificate for both
pharmaceutical products and plant audits.
Clinical trials in India cost US$ 25 million each, whereas in US they cost between US$
300-350 million each.
Indian pharmaceutical companies are spending 30-50% less on custom synthesis services
as compared to its global costs.
In India investigational new drug stage costs around US$ 10-15 million, which is almost
1/10th of its cost in US (US$ 100-150million).
Indian drug discovery and development outsourcing market is projected to grow at a rate
of 50 per cent to reach US$ 900 million in 2009.
Select companies provide biology-based services for target validation; notable examples
are Avesthagen, OcimumBiosolutionsand TCG Life Sciences.
Source: www.ibef.org
Clinical trials for NCEs constitute around 60 per cent of the total revenue mix, while 40
per cent is accounted for by bioavailabilty/bioequivalence (BA/BE) studies for generics
development. However, by volume, around 70 per cent of the work is directed towards
generic research.
The market for BA/BE studies in India was estimated to be around US$ 60 million to
US$ 70 million in 2006. It is estimated to reach US$ 150 million to US$ 200 million by
2010–11 growing at a CAGR of 18 to 20 per cent.
India‘s share of the outsourcing market is estimated to increase from 2.8 per cent in 2007
to 5.5 per cent in 2010.
The oncology pipeline is the richest in number, with a large number of pharmaceutical
and biotech companies focussing on oncology drugs.
Over 50 new oncology products are expected to be launched in the next five years with
new players entering the market.
Presently, the Indian oncology market stands at US$ 18.6 million and it is expected to
treble by 2010.
Ranbaxy Laboratories Ltd has entered into a strategic alliance with ZenotechLaboratories
Ltd Ranbaxy will market Zenotech'soncology cytotoxicinjectibleproducts under the Ranbaxy
label, leveraging its global marketing and distribution network in the key markets of Latin
America, including Brazil and Mexico, Russia and other CIS markets.
With revenues of US$ 200 million in 2009, organised pharmaceutical retail constitutes
just 2 per cent of the pharmaceutical retail market in India.
The government is contemplating the increase of FDI cap to up to 51 per cent in the case
of retail of single-brand products.
65 per cent of the population resides in rural areas with limited or absolutely no access to
medicines and other healthcare facilities.
With a growth rate of 39 per cent in 2006, the rural market has outstripped the growth in
the urban region across most of the therapeutic categories in both value and volume
terms.
Globally, sales of biological drugs are estimated to reach US$ 52 billion by 2010.
Leading Indian companies are intensifying their focus on the biotech segment.
Moreover, Indian players are also eyeing the huge opportunity presented by
biosimilarsacross the globe.
Further, biologics as a drug class is itself growing rapidly and estimates suggest that by
2014 seven of the top 10 drugs by sales globally would be biologics.
According to a report by IMS Health, the Indian generic manufacturers will grow to more
than US$ 70 billion as drugs worth approximately US$ 20 billion in annual sales faced
Indian generic drug makers received half a dozen more approvals from the US Food and
Drug Administration (FDA) in 2009, over the previous year. Dr Reddy's Laboratories
received the highest number of tentative and final approvals in 2009 at 32, followed by
Aurobindo at 26 and Wockhardt at 23.
Conclusion
Pharma industry has been facing the challenge of increasing their research inputs to be
able to compete with foreign giants. Till now the companies have been using the profit generated
from their operational activities to fund their research but now Indian companies are looking at a
trend of hiving-off or bee-off i.e., spinning off R&D into a separate company offers a unique
way of de-risking the balance sheet for companies involved in the high-risk high return game of
drugs discovery.
The analysis of the company’s accounts tells us that Cipla has been very effective in
performing as per the industry norms with the exception of Inventory management and
Average collection period. Thus it must look into these aspects to consolidate its position.
Sun pharma has had a very high sales and a very low credit period for its clients and
thus had a very high current and quick ratio thus the company must emphasize on these issues to
make use of their idle funds and increase their credit period to encourage client confidence.
Sun pharma has also brought down its debt level to zero which shows that the company is
investing more into research.
Dr. Reddy has also shown an encouraging performance and has given a high earnings
per share. The only factor for concern is the inventory levels of the company which needs
proper management.
Ranbaxy was a major player in the industry until 2007 when it ran into losses owing to
the number of acquisitions taken up by the company and the company has been acquired by the
Japanese pharma player Daiichi Sankyo which has been a good strategic move that will benefit
both the players.
If Pharma is to thrive in this new environment, though, it will have to make sweeping
changes throughout the value chain. Moreover, the incumbent management will have to move
fast. The disintegration of the traditional way of making and selling medicines could fuel another
round of mergers and acquisitions very different in nature from those that took place a few years
ago. Private equity houses and hedge funds could also play a significant role in reshaping the
sector.
Yet in some respects it does not matter that holds the reins, for Pharma cannot do
everything itself. It cannot train a new generation of research scientists unless there are scientists
to train. Nor can it make the medicines people need without society’s support. Several relatively
small changes would make a considerable difference. Investing in school science labs and
specialist teachers and giving science a more prominent place on the school curriculum would
encourage more pupils to study the sciences at university, thus creating a larger pool of
researchers on whom the industry could call. Altering the patent laws to recognize the value of
long-term research, rewarding the development of vaccines and cures more generously and
demonstrating a genuine commitment to the prevention of disease would likewise help to put the
industry on a firmer footing in its efforts to decode the molecular basis of disease – surely one of
the biggest and most worthwhile intellectual challenges the world faces.
The Government should take immediate steps to remove the anomalies in the Indian
Pharmacopoeia Commission created by it, and give necessary teeth to truly function as an
independent and autonomous scientific body.
www.business-standard.com/india/news/cipla-retains-top-slot-in-domestic-pharma-
market/38512
www.pharmabiz.com/article/detnews.asp?articleid=16738§ionid=50
www.expresspharmaonline.com/20100228/management03.shtml
www.ey.com/IN/en/SearchResults?
query=indian+pharma+industry&search_options=country_name
www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/
www.imsglobal.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/
?vgnextoid=0dce960144974210VgnVCM100000ed152ca2RCRD&vgnextfmt=default
www.pwc.com/.../pharma.../pharma-2020/pharma-2020-vision-path.jhtml
http://www.ibef.org/
DATABASES:
Capitalline
Corporate websites